Affinage

Showing MTLNMOXI is a alias.

MTLN

Mitoregulin · UniProt Q8NCU8

Length
56 aa
Mass
6.5 kDa
Annotated
2026-06-10
80 papers in source corpus 8 papers cited in narrative 8 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MTLN (MOXI/Mitoregulin/MPM/LEMP) encodes a conserved ~56-amino acid micropeptide of the inner mitochondrial membrane that functions as a regulator of oxidative metabolism and respiratory efficiency (PMID:29949755, PMID:32393776). It enhances mitochondrial fatty acid β-oxidation through association with the mitochondrial trifunctional protein complex, such that loss of MTLN shifts fuel preference from fatty acids to carbohydrates and, under high-fat-diet challenge, produces obesity, elevated serum triglycerides, and depletion of TCA cycle intermediates (PMID:29949755, PMID:36174793). MTLN also constrains respiratory chain output by binding the complex I subunit NDUFA7 to inhibit complex I activity and lower the NAD+/NADH ratio (PMID:34478872). Through these effects on mitochondrial respiration it promotes myogenic differentiation — an activity rescued downstream by PGC-1α — and is required for normal skeletal muscle fiber size, regeneration, and development across species (PMID:31296841, PMID:32393776). In the heart, MTLN drives cardiomyocyte proliferation and growth by interacting with PTPMT1 to activate AKT signaling (PMID:39163918). Beyond mitochondria, MTLN undergoes T49-phosphorylation-dependent nuclear translocation upon TGF-β1 stimulation, where it bridges N-acetyltransferase 14 (Nat14) and c-Jun to activate the collagen I promoter and promote kidney fibrosis (PMID:36804379). The micropeptide self-associates into pore-like oligomeric complexes in the mitochondrial membrane [PMID:bio_10.1101_2024.07.10.601956].

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2018 High

    Established that MTLN is a functional mitochondrial micropeptide rather than noncoding sequence, defining its core role in fatty acid β-oxidation via the trifunctional protein complex.

    Evidence Subcellular fractionation, reciprocal Co-IP with MTP, isolated-mitochondria oxidation assays, and KO/transgenic mouse metabolic phenotyping

    PMID:29949755

    Open questions at the time
    • Whether MTLN acts catalytically or as a structural/regulatory scaffold for MTP was not resolved
    • Direct binding stoichiometry to MTP subunits not defined
  2. 2019 High

    Linked MTLN's mitochondrial respiratory function to a developmental output by showing it is required for myogenic differentiation, placing it upstream of PGC-1α-driven biogenesis.

    Evidence siRNA/overexpression in C2C12, KO mouse muscle phenotyping, respiration/ATP assays, and PGC-1α epistasis rescue

    PMID:31296841

    Open questions at the time
    • Molecular link between MTLN and PGC-1α not defined
    • Whether differentiation defect is purely metabolic or signaling-dependent unclear
  3. 2020 High

    Demonstrated evolutionary conservation of MTLN's myogenic function via cross-species rescue, confirming a generalizable role in muscle formation.

    Evidence Zebrafish loss-of-function rescued by mouse LEMP, Co-IP with mitochondrial proteins, satellite-cell RNA-seq

    PMID:32393776

    Open questions at the time
    • Reported plasma membrane localization not mechanistically explained
    • Identities/relevance of additional mitochondrial partners not resolved
  4. 2021 High

    Identified a direct respiratory-chain target, showing MTLN binds NDUFA7 to inhibit complex I and tune the NAD+/NADH ratio, connecting it to redox balance and tumor cell behavior.

    Evidence MPM–NDUFA7 Co-IP, complex I activity and NAD+/NADH assays, NDUFA7 knockdown epistasis, NAD+ precursor rescue, migration/metastasis models, miR-17-5p binding assay

    PMID:34478872

    Open questions at the time
    • How MTLN reconciles complex I inhibition with enhanced β-oxidation/respiration is unresolved
    • Structural basis of NDUFA7 binding unknown
  5. 2022 Medium

    Confirmed the whole-organism metabolic consequence of MTLN loss, establishing it as required for efficient oxidative metabolism of respiratory substrates in vivo.

    Evidence Mtln KO mice on high-fat diet with MRI fat-mass imaging and serum metabolite/TCA-intermediate measurement

    PMID:36174793

    Open questions at the time
    • No in vitro mechanistic reconstitution
    • Single-lab phenotype without orthogonal molecular mechanism
  6. 2023 High

    Revealed an unexpected non-mitochondrial, transcriptional function: TGF-β1-induced, T49-phosphorylation-dependent nuclear MTLN bridges Nat14 and c-Jun to drive fibrotic gene expression.

    Evidence BiFC partner identification, fractionation/live imaging of translocation, collagen I promoter luciferase, T49A mutagenesis, KO and ASO fibrosis mouse models

    PMID:36804379

    Open questions at the time
    • Kinase responsible for T49 phosphorylation not identified
    • How a mitochondrial micropeptide is retargeted to the nucleus mechanistically unclear
  7. 2024 High

    Extended MTLN's signaling role to cardiac growth, defining a PTPMT1–AKT axis that drives cardiomyocyte proliferation.

    Evidence MPM–PTPMT1 Co-IP, KO mouse cardiac phenotyping, RNA-seq, PTPMT1 knockdown and AKT inhibition epistasis rescues

    PMID:39163918

    Open questions at the time
    • How mitochondrial MTLN engages PTPMT1 to activate cytoplasmic AKT is undefined
    • Relationship to MTLN's metabolic functions in cardiomyocytes unclear
  8. 2024 Medium

    Proposed a structural basis for MTLN function, showing it self-associates into likely hexameric pore-like complexes in the mitochondrial membrane.

    Evidence Endogenous–tagged Co-IP, native PAGE (~66 kDa complex), structure modeling, in vitro oligomerization of synthetic protein (preprint)

    PMID:bio_10.1101_2024.07.10.601956

    Open questions at the time
    • Hexameric model not validated at atomic resolution
    • Functional consequence of pore formation (e.g. transport, partner scaffolding) not demonstrated
    • Preprint, not peer-reviewed

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how a single ~56-aa micropeptide integrates seemingly opposing mitochondrial activities (β-oxidation enhancement vs complex I inhibition) and switches to a distinct nuclear transcriptional role, and whether its oligomeric pore structure underlies these functions.
  • Unifying biochemical mechanism linking metabolic, signaling, and transcriptional roles not established
  • No high-resolution structure of MTLN in any partner complex

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 2 GO:0005198 structural molecule activity 1 GO:0060090 molecular adaptor activity 1 GO:0140096 catalytic activity, acting on a protein 1
Localization
GO:0005739 mitochondrion 3 GO:0005634 nucleus 1 GO:0005886 plasma membrane 1
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 3 R-HSA-162582 Signal Transduction 1 R-HSA-74160 Gene expression (Transcription) 1
Complex memberships
MTLN homo-oligomer (likely hexameric pore)mitochondrial trifunctional protein complex

Evidence

Reading pass · 8 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 MOXI (MTLN) is a conserved muscle-enriched micropeptide that localizes to the inner mitochondrial membrane and associates with the mitochondrial trifunctional protein (MTP) complex; knockout mice show diminished fatty acid β-oxidation in isolated heart and skeletal muscle mitochondria, while transgenic overexpression enhances β-oxidation, and knockout mice preferentially oxidize carbohydrates over fatty acids. Subcellular fractionation/localization, Co-immunoprecipitation with MTP complex, isolated mitochondria fatty acid oxidation assays, transgenic overexpression and knockout mouse models, isolated perfused heart metabolic assay, exercise capacity testing Cell reports High 29949755
2019 MPM (MTLN) micropeptide localizes to mitochondria and is required for myogenic differentiation; MPM silencing inhibits C2C12 myoblast differentiation into myotubes, MPM overexpression stimulates it, and MPM KO mice show smaller skeletal muscle fibers and impaired muscle regeneration; mechanistically, MPM increases mitochondrial oxygen consumption and ATP production, and ectopic PGC-1α expression rescues the inhibitory effect of MPM silencing on myogenic differentiation. siRNA knockdown, overexpression in C2C12 cells, MPM KO mouse model, mitochondrial respiration assay (oxygen consumption, ATP production), PGC-1α epistasis rescue experiment, immunofluorescence localization Cell death & disease High 31296841
2020 LEMP (MTLN) is a 56-aa micropeptide that localizes to both the plasma membrane and mitochondria, associates with multiple mitochondrial proteins, and promotes skeletal muscle formation; LEMP knockdown impairs zebrafish muscle development, which is rescued by mouse LEMP expression, demonstrating evolutionarily conserved function in myogenesis. Subcellular localization by fluorescence imaging, Co-immunoprecipitation with mitochondrial proteins, zebrafish loss-of-function (morpholino/genetic), cross-species rescue experiment with mouse LEMP, satellite cell RNA-seq Cell death & disease High 32393776
2021 MPM (MTLN) interacts with NDUFA7 and inhibits mitochondrial complex I activity; MPM overexpression reduces complex I activity and lowers the NAD+/NADH ratio, while MPM silencing increases complex I activity and elevates NAD+/NADH; NDUFA7 knockdown attenuates the effect of MPM silencing on complex I. The NAD+ precursor nicotinamide abrogates MPM's inhibitory effect on hepatoma cell migration. Additionally, miR-17-5p binds to MPM mRNA and inhibits MPM expression. Co-immunoprecipitation (MPM–NDUFA7), mitochondrial complex I activity assay, NAD+/NADH measurement, siRNA knockdown (MPM, NDUFA7), nicotinamide rescue experiment, luciferase/binding assay for miR-17-5p, in vitro migration/invasion assays, in vivo metastasis models Molecular therapy : the journal of the American Society of Gene Therapy High 34478872
2022 Mitoregulin (Mtln/MTLN) knockout mice develop obesity on a high-fat diet with increased fat accumulation, elevated serum triglycerides and other oxidation substrates, and exhaustion of TCA cycle intermediates, indicating that Mtln is required for efficient oxidative metabolism of respiratory substrates in mitochondria. Mtln KO mouse model, magnetic resonance live imaging (fat mass), serum metabolite measurement (triglycerides, TCA intermediates), high-fat diet challenge Biochimie Medium 36174793
2023 MOXI (MTLN) translocates from mitochondria/cytoplasm to the nucleus upon TGF-β1 stimulation; in the nucleus, MOXI forms a complex with N-acetyltransferase 14 (Nat14) and transcription factor c-Jun, enhancing collagen I gene promoter activity. Phosphorylation at T49 is required for MOXI nuclear localization and complex formation. MOXI deletion protects mice against kidney fibrosis, and antisense oligonucleotide knockdown also protects against fibrosis. Bimolecular fluorescence complementation (BiFC) identifying Nat14 and c-Jun as binding partners, subcellular fractionation and live imaging for nuclear translocation, luciferase promoter activity assay (collagen I), site-directed mutagenesis (T49A point mutation), KO mouse models (folic acid and UUO fibrosis), antisense oligonucleotide treatment Kidney international High 36804379
2024 MPM (MTLN) promotes cardiomyocyte proliferation and heart growth by interacting with PTPMT1 to activate the AKT pathway; MPM KO mice show reduced left ventricular mass and myocardial thickness, MPM silencing downregulates cell cycle-promoting genes and reduces cardiomyocyte proliferation, and PTPMT1 silencing attenuates MPM-induced AKT activation; AKT pathway inhibition abrogates MPM-promoted cardiomyocyte proliferation. Co-immunoprecipitation (MPM–PTPMT1), MPM KO mouse model, RNA-seq in H9c2 cells, gain- and loss-of-function (siRNA/overexpression), AKT pathway inhibition rescue experiment, proliferation assays, cardiac phenotyping Biochimica et biophysica acta. Molecular cell research High 39163918
2024 Mitoregulin (Mtln/MTLN) self-associates to form likely hexameric pore-like structures in the mitochondrial membrane; endogenous Mtln co-immunoprecipitates with epitope-tagged Mtln at high efficiency, Mtln primarily exists in a ~66 kDa complex, protein modeling suggests a hexameric arrangement, and synthetic Mtln protein forms oligomeric complexes in vitro. Co-immunoprecipitation (endogenous–epitope-tagged), native PAGE gel assessment of complexes in cells and tissues, protein structure modeling/simulation, in vitro oligomerization of synthetic Mtln bioRxivpreprint Medium bio_10.1101_2024.07.10.601956

Source papers

Stage 0 corpus · 80 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1993 DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proceedings of the National Academy of Sciences of the United States of America 162 7690961
2015 Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PloS one 160 25774992
2020 The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility and sterility 143 32111479
2018 MOXI Is a Mitochondrial Micropeptide That Enhances Fatty Acid β-Oxidation. Cell reports 141 29949755
1994 cdc25 is one of the MPM-2 antigens involved in the activation of maturation-promoting factor. Molecular biology of the cell 95 8019000
1997 Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. American journal of respiratory and critical care medicine 93 9310000
1991 Isolation and characterization of the moxJ, moxG, moxI, and moxR genes of Paracoccus denitrificans: inactivation of moxJ, moxG, and moxR and the resultant effect on methylotrophic growth. Journal of bacteriology 87 1657871
1989 Mitosis-specific monoclonal antibody MPM-2 inhibits Xenopus oocyte maturation and depletes maturation-promoting activity. Proceedings of the National Academy of Sciences of the United States of America 80 2662192
2000 Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469. The Journal of biological chemistry 73 10942766
1993 At least two kinases phosphorylate the MPM-2 epitope during Xenopus oocyte maturation. The Journal of cell biology 69 7693720
1999 A hyperphosphorylated form of RNA polymerase II is the major interphase antigen of the phosphoprotein antibody MPM-2 and interacts with the peptidyl-prolyl isomerase Pin1. Journal of cell science 67 10393805
1988 Cell-cycle modulation of MPM-2-specific spindle pole body phosphorylation in Aspergillus nidulans. Cell motility and the cytoskeleton 65 3052873
2019 A novel mitochondrial micropeptide MPM enhances mitochondrial respiratory activity and promotes myogenic differentiation. Cell death & disease 62 31296841
2015 SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 58 25611229
2012 Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung cancer (Amsterdam, Netherlands) 58 22459204
2020 The micropeptide LEMP plays an evolutionarily conserved role in myogenesis. Cell death & disease 50 32393776
2021 Downregulation of a mitochondrial micropeptide, MPM, promotes hepatoma metastasis by enhancing mitochondrial complex I activity. Molecular therapy : the journal of the American Society of Gene Therapy 41 34478872
2021 The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. The Lancet. Digital health 34 34332931
2020 Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). Theranostics 34 32042342
1997 MPM-2 antibody-reactive phosphorylations can be created in detergent-extracted cells by kinetochore-bound and soluble kinases. Journal of cell science 34 9378753
1991 A novel M phase-specific H1 kinase recognized by the mitosis-specific monoclonal antibody MPM-2. Developmental biology 33 1995402
2013 Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). PloS one 32 23976967
2016 Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung cancer (Amsterdam, Netherlands) 30 27133741
2009 Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung cancer (Amsterdam, Netherlands) 30 19233506
2009 Regulation of inositol 1,4,5-trisphosphate receptor type 1 function during oocyte maturation by MPM-2 phosphorylation. Cell calcium 30 19482353
2020 Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. International journal of molecular sciences 27 32708306
2017 Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers 27 28862644
2007 Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A. The Biochemical journal 27 17212588
2020 Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2. Cells 26 32260559
2004 Multisite phosphorylation of Pin1-associated mitotic phosphoproteins revealed by monoclonal antibodies MPM-2 and CC-3. BMC cell biology 26 15171797
2008 An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Molecular bioSystems 25 19081932
1998 The G2 block induced by DNA damage: a caffeine-resistant component independent of Cdc25C, MPM-2 phosphorylation, and H1 kinase activity. Cancer research 24 9635591
1997 Partial characterization of the MPM-2 phosphoepitope. Experimental cell research 22 9056407
1994 The MPM-2 antibody inhibits mitogen-activated protein kinase activity by binding to an epitope containing phosphothreonine-183. Molecular biology of the cell 22 7532473
1997 MPM-2 epitope sequence is not sufficient for recognition and phosphorylation by ME kinase-H. FEBS letters 20 9303547
2020 Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. Cancers 19 33065998
1993 Localization of MPM-2 recognized phosphoproteins and tubulin during cell cycle progression in synchronized Vicia faba root meristem cells. Cell biology international 19 8220311
2022 Mitochondrial peptide Mtln contributes to oxidative metabolism in mice. Biochimie 18 36174793
2020 Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers 18 33374980
2018 Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. International journal of molecular sciences 17 29342862
2018 In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM). International journal of molecular sciences 17 29701689
2015 MTA1 promotes metastasis of MPM via suppression of E-cadherin. Journal of experimental & clinical cancer research : CR 17 26689197
2021 The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Journal of assisted reproduction and genetics 16 34455507
2020 The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review. Frontiers in oncology 16 33014860
2013 Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM). Annals of surgical oncology 15 24306661
1998 A phosphatase activity in Xenopus oocyte extracts preferentially dephosphorylates the MPM-2 epitope. FEBS letters 15 9539156
2023 Mitochondrial micropeptide MOXI promotes fibrotic gene transcription by translocation to the nucleus and bridging N-acetyltransferase 14 with transcription factor c-Jun. Kidney international 14 36804379
2022 PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM. British journal of cancer 14 35794237
2022 Long non-coding RNA TILR constitutively represses TP53 and apoptosis in lung cancer. Oncogene 13 36522487
2021 Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Lung cancer (Amsterdam, Netherlands) 13 33561782
2021 Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British journal of cancer 13 34088988
2012 Determination of mammalian cell counts, cell size and cell health using the Moxi Z mini automated cell counter. Journal of visualized experiments : JoVE 13 22760092
1998 Okadaic acid induces appearance of the mitotic epitope MPM-2 in SV40-infected CV-1 cells with a >G2-phase DNA content. Cytometry 12 9551601
2020 Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 11 31916017
2021 Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment. Therapeutic advances in medical oncology 10 34917175
1993 Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma. European journal of haematology 10 8436213
2022 Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells. Frontiers in cell and developmental biology 9 35392170
2024 Identification and exploration of a new M2 macrophage marker MTLN in alveolar echinococcosis. International immunopharmacology 8 38457984
1999 Heat shock-induced alterations in phosphorylation of the largest subunit of RNA polymerase II as revealed by monoclonal antibodies CC-3 and MPM-2. Biochemistry and cell biology = Biochimie et biologie cellulaire 8 10546900
1997 Isolation and characterization of MPM-2-reactive sperm proteins: homology to components of the outer dense fibers and segmented columns. Biology of reproduction 8 9241037
2021 The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM). International journal of molecular sciences 7 34638565
2018 BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival. Cancer genetics 7 30553477
2022 Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO open 6 35427834
2018 Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures. International journal of molecular sciences 6 30301262
2016 Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells. Cancer investigation 6 27438907
1999 How should we treat malignant pleural mesothelioma (MPM)? Acta chirurgica Hungarica 6 10439104
2023 Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). Clinical lung cancer 5 37301693
2020 MPM motifs of the yeast SKT protein Trk1 can assemble to form a functional K+-translocation system. Biochimica et biophysica acta. Biomembranes 5 33245894
2019 Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). Scientific reports 5 31308438
2022 KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM). NAR cancer 4 35910692
2024 Moxie begets MOXI: The journey to a novel hypothesis about Mu-opioid and OXytocin system Interactions. Comprehensive psychoneuroendocrinology 3 39104824
1995 Immunocytochemical study of lampbrush chromosomes of the urodele Pleurodeles waltl: axial granules are recognized by the mitosis-specific monoclonal antibody MPM-2. Biology of the cell 3 7549914
1992 MPM-12: a monoclonal antibody that predominantly stains mitotic cells and recognizes a protein kinase. European journal of cell biology 3 1379180
2025 TET3-Interacting LncRNA TILR Is Essential for DNA Hydroxymethylation-Mediated Neuroprotection After Ischemic Stroke. Stroke 2 40665901
2022 The marine natural product mimic MPM-1 is cytolytic and induces DAMP release from human cancer cell lines. Scientific reports 2 36114339
2019 Endophthalmitis after dropless (Tri-Moxi injection) cataract surgery. European journal of ophthalmology 2 31155929
2025 FL496, an FL118-derived small molecule, induces growth inhibition, senescence, and apoptosis of malignant pleural mesothelioma (MPM) cells, and exhibits anti-MPM tumor efficacy strikingly superior to the pemetrexed-cisplatin combination. Journal of experimental & clinical cancer research : CR 1 41121175
2024 Micropeptide MPM regulates cardiomyocyte proliferation and heart growth via the AKT pathway. Biochimica et biophysica acta. Molecular cell research 1 39163918
2023 Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing. Cancers 1 37345150
2023 Two rare copy number variants involving loss of NPHP1, MALL, and MTLN genes contribute to nephronophthisis-induced nephropathy progression in a family: A case report. Nigerian journal of clinical practice 0 37203120

Missed literature

Know a paper Affinage missed for MTLN? Flag it for the maintainers and the community.

No submissions yet.